Study Group: Cardiac Electrophysiologists (US)
Council Members in this Study Group: 319
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Hossein ArdehaliAssistant Professor
Northwestern University, Feinberg School of Medicine
Hossein Ardehali, MD, PhD, is Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research...
- Michael Kim
Associate Professor
Northwestern University, Feinberg School of MedicineMichael Kim, MD, is Associate Professor at Feinberg School of Medicine, Northwestern University, Illinois. He has served as Cardiac Electrophysiologist at Health Partners and Regions Hospital in Minnesota and also as Associate Professor at the University...
Daniel WeissPresident
Weiss Consulting Groups, Inc.Daniel Weiss, MD, FACC, is a Clinical Cardiac Electrophysiologist with Florida Arrhythmia Consultants and the Founder and President of his own consultancy, Weiss Consulting Groups, which provides consultation services to the business world on medical...
David MartinDirector of the Cardiac Arrhythmia Service
LAHEY CLINICDavid Martin, MD, FRCP, FACC, FACP, FHRS is the Director of the Arrhythmia Service and Program Director of Cardiac Electrophysiology Fellowship at Lahey Clinic in Burlington, Massachusetts. He also holds appointments at Harvard and Tufts medical schools....
- Byron Lee
Assistant Professor
UNIVERSITY OF CALIFORNIA, SAN FRANCISCOByron Lee, MD, is an Assistant Professor of Medicine in the Division of Cardiology at University of California San Francisco. Dr. Lee is board certified in Cardiovascular Disease and Clinical Cardiac Electrophysiology. He has expertise in treatments for...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
A new drug that would change the way we treat Atrial Fibrillation!
May 20, 2008
Landmark ATHENA Study findings with dronedarone presented during the annual Heart Rhythm meeting in San Francisco | www.medscape.com
Atrial fibrillation management. New anti-arrhythmic medication.
-
October 18, 2007
Analysis by: Daniel Weiss, President,Medtronic Pulls Heart Device Wires | www.thestreet.com
The current recall is yet another in the world of cardiac rhythm devices. The ICD market is already shakey and may be adversely affected. Will Medtronic's reputation suffer?
-
TB-402 - the type of anticoagulant patients and physicians are looking for as a warfarin replacement
September 17, 2007
Analysis by: Daniel Weiss, President,ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 | www.pipelinereview.com
TB-402 is a new anticoagulant candidate that seeks to fill a desperate unmet need in a variety of different medical conditions. It would be easily administered with a low risk of patient noncompliance, have reversible effects, and potentially safer than currently available alternatives.
-
March 26, 2007
St. Jude Medical Announces FDA Approval of First U.S. Heart Failure Device with AF Suppression Technology | salesandmarketingnetwork.com
1. This technology has been in SJM pacemakers for long enough that we know AF is not eliminated - merely reduced in amount
2. Reduction in AF burden does not translate into reduced need for anticoagulation in this high risk population
3. Reduction in AF burden does not translate into reduction in clinical end-points such as stroke
4. The AF-suppression algorithm increases heart rate significantly and may (in theory) undermine the benefits of CRT -
New studies suggest DES may improve outcome in the setting of AMI
September 19, 2006
Analysis by: Hossein Ardehali, Assistant Professor,NEJM Articles on DES in MI | content.nejm.org
The studies reported in the recent issues of NEJM are significant in that they provide evidence that DES in the setting of AMI with ST elevation may improve outcome. Taxel-eluting stents showed nonsignificant improvement in adverse cardiac events, but sirolimus-eluting stents showed a significant reduction in target vessel revascularization
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Owner
- Director
- Partner
Related Study Groups
GLG Live Meetings with this Study Group's Leading Experts (?)
July 28, 2009 | New York
GLG Seminar: (NYC) Antiarrhythmics with Michael Kim, MDGLG Webcasts & Teleconferences
Leading Experts in Cardiac Electrophysiologists (US) have not participated in any GLG webcasts.